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Stringent control of the NF-kB and type I inter-
feron signaling pathways is critical to effective host
immune responses, yet the molecular mechanisms
that negatively regulate these pathways are poorly
understood. Here, we show that NLRC5, a member
of the highly conserved NOD-like protein family,
can inhibit the IKK complex and RIG-I/MDA5 func-
tion. NLRC5 inhibited NF-kB-dependent responses
by interacting with IKKa and IKKb and blocking their
phosphorylation. It also interacted with RIG-I and
MDA5, but not with MAVS, to inhibit RLR-mediated
type I interferon responses. Consistent with these
observations, NLRC5-specific siRNA knockdown
not only enhanced the activation of NF-kB and its
responsive genes, TNF-a and IL-6, but also pro-
moted type I interferon signaling and antiviral immu-
nity. Our findings identify NLRC5 as a negative regu-
lator that blocks two central components of the
NF-kB and type I interferon signaling pathways and
suggest an important role for NLRC5 in homeostatic
control of innate immunity.
INTRODUCTION
The innate immune response, elicited through the detection of
pathogen-associated molecular patterns (PAMPs), provides the
first line of defense against invading microorganisms. PAMP
recognition depends on several classes of pattern recognition
receptors (PRRs), including Toll-like receptors (TLRs), NOD-like
receptors (NLRs), and RIG-I-like receptors (RLRs) (Akira et al.,
2006; Honda and Taniguchi, 2006; Inohara et al., 2005; Medzhi-
tov, 2007; Meylan et al., 2006; Ting et al., 2006). Activation of
most TLRs leads to the recruitment of a common adaptor,
MyD88, and in turn to a series of downstream signaling events
that culminate in NF-kB activation (Akira et al., 2006; Chen,
2005; Hayden and Ghosh, 2008). By contrast, activation ofRLRs (RIG-I and MDA5) by double- and single-stranded RNAs
or certain viruses (Hornung et al., 2006; Kato et al., 2006; Pichl-
mair et al., 2006) results in recruitment of the MAVS protein (mito-
chondrial antiviral signaling; also called VISA, IPS-1 and Cardif),
which further activates the downstream signaling molecules
TBK1/IKKi and IRF3 for type I interferon responses, as well as
IKK molecules for NF-kB activation (Meylan et al., 2006). Besides
their roles in innate immunity and inflammation, TLR-mediated
signaling pathways have been shown to play an important role
in the control of regulatory T cell function (Liu et al., 2006;
Peng et al., 2005, 2007; Sutmuller et al., 2006).
Because uncontrolled immune responses can be harmful,
even fatal, to the host (Liew et al., 2005), NF-kB activation and
type I interferon signaling must be tightly regulated to maintain
immune balance in the organism. Despite the importance of
the IKK complex as a central transducer of signaling from various
stimuli, leading to the activation of the NF-kB pathway, and of
RLRs as critical receptors in type I interferon signaling (Chen,
2005; Honda and Taniguchi, 2006), the molecular mechanisms
responsible for IKK activation and RLR-mediated signaling
remain poorly understood.
NLRs represent a large family of intracellular PRRs that are
characterized by a conserved nucleotide-binding and oligomer-
ization domain (NOD) and a leucine-rich repeat (LRR) region, and
are involved in the activation of diverse signaling pathways (Akira
et al., 2006; Inohara et al., 2005; Meylan et al., 2006). Several
NLRs, such as NOD1, NOD2 and NALP3, have been extensively
studied and shown to activate signaling pathways once they
encounter relevant PAMPs (Akira et al., 2006; Chen, 2005;
Inohara et al., 2005; Meylan et al., 2006). NALP3 inflammasome,
for example, functions as a crucial component in the adjuvant
effect of aluminum and asbestos (Dostert et al., 2008; Eisenbarth
et al., 2008). More recently, NLRX1 was demonstrated to func-
tion as a mitochondrial protein that interacts with the mitochon-
drial adaptor MAVS to inhibit the RIG-I-mediated signaling
pathway and triggers the generation of reactive oxygen species
as well (Moore et al., 2008; Tattoli et al., 2008). These studies
suggest that understanding the function and mechanisms of
these innate immune receptors or regulators may aid in devel-
oping more effective strategies for the immunological treatmentCell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc. 483
Figure 1. DomainOrganization, Expression,
and Intracellular Localization of Human and
Mouse NLRC5
(A) Domain organization of human and mouse
NLRC5 proteins. CARD, caspase recruitment
domain; NOD, nucleotide binding domain; LRR,
leucine rich repeats.
(B) Western blot analysis of HA-tagged NLRC5
and mNLRC5 protein expression in 293T cells.
(C) Human and mouseNLRC5mRNAs were deter-
mined in different tissues determined by real-time
PCR analysis.
(D) Expression of mNLRC5 mRNA in RAW264.7
cells was determined by real-time PCR analysis
after LPS, intracellular poly (I:C) stimulation or
VSV-eGFP infection.
(E) Immunoblot analysis of mNLRC5 protein
expression after LPS stimulation or VSV-eGFP
infection (left panel). The relative protein levels of
mNLRC5 were quantified by the band density
scanning of western blot images and plotted
against time (hr) after LPS treatment or VSV infec-
tion (right panel).
(F) Both wild-type and MyD88-deficient macro-
phages were treated with LPS, and mNLRC
mRNA expression was determined by real-time
PCR analysis.
See also Figure S1.of inflammation-associated diseases (Karin et al., 2006; Wang
et al., 2008).
Given that the NLR protein family is involved in many biological
processes and functions as proinflammatory receptors as well
as negative regulators, we hypothesized that some NLR mem-
bers may play a critical regulatory role in the control of NF-kB
and type I interferon signaling. Here we report the identification
of NLRC5 as a potent negative regulator of NF-kB and IRF3
activation. It strongly inhibits NF-kB-dependent responses by
interacting with IKKa and IKKb and blocking their phosphoryla-
tion. It also interacts with RIG-I and MDA5, but not with MAVS,
to potently inhibit RLR-mediated type I interferon responses.
As a key negative regulator of NF-kB and type I interferon sig-
naling, NLRC5 may serve as a useful target for manipulating
immune responses against infectious or inflammation-associ-
ated diseases, including cancer.
RESULTS
Molecular Cloning and Characterization of NLRC5
As a member of the NLR protein family, NLRC5 contains a
CARD-like domain, a central NOD domain and a large LRR484 Cell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc.E
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inregion (Figure 1A), but its biological func-
tion remains unknown (Chen et al., 2009;
Dowds et al., 2003). To determine the
function of NLRC5, we cloned full-length
human and murine NLRC5 complemen-
tary DNAs (cDNAs) by rapid amplification
of cDNA ends (RACE) (Figure 1A). There
was a 64% amino acid sequence identity
between the human and murine proteins.xpression of both HA-tagged NLRC5 and mNLRC5 was dem-
nstrated by western blotting with an anti-HA antibody (Fig-
re 1B). Both human and murine NLRC5 mRNAs were strongly
xpressed in spleen, thymus, and lung (Figure 1C), suggesting
at this molecule is biologically conserved in these tissues.
To further demonstrate the protein expression of NLRC5 in
ifferent cell types, we generated polyclonal antibodies against
ndogenous NLRC5 and mNLRC5 (Figures S1A–S1E avail-
ble online), which readily detected these proteins in human
EK293T (293T) cells, human THP1 cells or mouse RAW264.7
ells (Figure S1F). To determine whether NLRC5 expression
ould be regulated in response to TLR stimulation or virus infec-
on, we treated RAW264.7 cells with LPS, intracellular poly(I:C),
r infection with vesticular stomatitis virus-enhanced green fluo-
scent protein (VSV-eGFP), which are known to activate the
F-kB or type I IFN pathway (Yoneyama and Fujita, 2009).
eal-time PCR and western blot analyses revealed strong upre-
ulation of mNLRC5 at both the mRNA and protein levels, which
eaked at 6 hr after LPS treatment (Figures 1D and 1E and
igure S1G). In contrast, we observed only a weak increase of
NLRC5 mRNA and little or no change in mNLRC5 protein after
tracellular poly(I:C) treatment or VSV infection (Figures 1D and
Figure 2. NLRC5 Inhibits NF-kB Activation
Induced by IL-1b, LPS, TNF-a, and Their
Downstream Signaling Molecules
(A) 293T cells were transfected with an NF-kB-luc
reporter plasmid and TLR4 plasmid (for LPS treat-
ment), together with an empty vector or NLRC5
construct, and analyzed for NF-kB-dependent
luciferase activity (fold induction) after treatment
with IL-1b, LPS, or TNF-a.
(B) 293T cells were transfected with MyD88,
TRAF6, IKKa, IKKb, or p65, along with NF-kB-luc.
(C) 293T cells were transfected with NOD1 or
NOD2, along with NF-kB-luc.
(D) Detection of endogenous NF-kB DNA binding
activity in a gel-mobility shift assay. Oct-1/DNA-
binding complexes served as a loading control
for nuclear extracts.
(E) Human THP-1 cells and murine embryonic
fibroblasts (MEF) were transfected with the
NF-kB-luc reporter plasmid, together with (or
without) NLRC5 or mNLRC5 plasmid, and then
analyzed for NF-kB-dependent luciferase activity
after LPS treatment (***p < 0.001).
See also Figure S2.1E), consistent with a previous study showing that VSV infection
is a weak NF-kB inducer (Ishikawa and Barber, 2008). To further
explore the mechanisms by which NLRC5 is regulated, we per-
formed similar experiments with wild-type and MyD88 knockout
(KO) macrophages and found that upregulation of mNLRC5 was
completely abolished when MyD88 KO macrophages were
stimulated with LPS (Figure 1F), indicating that the expression
of mNLRC5 itself is controlled by the NF-kB signaling pathway.
To determine the cellular localization of NLRC5, we trans-
fected 293T cells with NLRC5-GFP fusion DNA and found that
NLRC5-GFP was present in the cytoplasm, but not in the nucleus
or mitochondria (Figures S1H–S1I), suggesting that NLRC5 is
a cytosolic protein. No change in the cellular localization of
NLRC5 was observed after LPS treatment (Figures S1I–S1K).
NLRC5 Is a Potent Negative Regulator of NF-kB
Activation Induced by TLR Ligands
To determine whether NLRC5 is involved in TLR- and/or
cytokine-mediated NF-kB activation, we transfected 293T or
293T/TLR4 cells with NF-kB-luc reporter DNA, with or withoutCell 141, 483–4the NLRC5 plasmid, and then treated
them with interleukin (IL)-1b, TNF-a or
LPS. Results in Figure 2A show that
NLRC5 potently inhibited NF-kB activa-
tion induced by IL-1b, TNF-a or LPS.
We next sought to identify potential sig-
naling molecules that activated the NF-
kB-luc reporter. Expression of MyD88,
TRAF6, IKKa, or IKKb strongly induced
NF-kB-luc activity, but such activity was
inhibited whenNLRC5was cotransfected
at increasing concentrations (Figure 2B).
In contrast, NLRC5 did not inhibit p65-
mediated NF-kB-luc activity, suggestingthat it may interact with IKK signaling molecules upstream of
p65 to block NF-kB activation (Figure 2B). The control plasmids
NOD1 and NOD2 enhanced rather than inhibited NF-kB activity
(Figure 2C), consistent with previous studies (Inohara et al.,
1999; Ogura et al., 2001).
Since LPS can also activate the type I IFN pathway through an
adaptor TRIF molecule, we asked whether NLRC5 can inhibit
LPS-induced IFN-b-luc activity (which requires cooperation
between IRF3 and NF-kB activation) or interferon-stimulated
response element (ISRE)-luc activity (which requires IRF3 activa-
tion only) (Zhong et al., 2008). Functional assays showed that
NLRC5 inhibited LPS- or TRIF-induced NF-kB-luc and IFN-b-
luc activities, but had no effects on ISRE-luc activity (Figures
S2A and S2B). Further experiments demonstrated that NLRC5
strongly inhibited R848-induced NF-kB-luc activity and weakly
inhibited IFN-b-luc activity, but did not inhibit ISRE-luc activity
(Figure S2C). Thus, NLRC5 strongly inhibits NF-kB activation
induced by different TLR ligands and weakly blocks IFN-b activa-
tion mainly due to its requirement for NF-kB activity, but has no
apparent effect on ISRE activity.96, April 30, 2010 ª2010 Elsevier Inc. 485
To determine whether the observed NLRC5-mediated inhibi-
tion of NF-kB-luc activity is associated with endogenous NF-kB
activity, we performed experiments with a gel-mobility shift
assay. IKKb expression allowed endogenous NF-kB to bind to
the biotin-HRP-labeled DNA with NF-kB binding sites, but this
activity was completely inhibited when NLRC5 was cotrans-
fected. However, NLRC5 failed to inhibit p65-mediated NF-kB
activation (Figure 2D), consistent with results obtained with the
NF-kB-luc reporter assay. To substantiate these findings, we
found that like its human homolog, mNLRC5 strongly inhibited
NF-kB activation by MyD88, TRAF6, IKKa and IKKb, but not
by p65 (Figure S2D). Moreover, NLRC5- or mNLRC5-mediated
NF-kB inhibition in 293T cells could be extended to THP-1 cells
and murine embryonic fibroblasts (MEFs) (Figure 2E). Taken
together, these results suggest that NLRC5 functions as a nega-
tive regulator of NF-kB activation induced by TNF-a, IL-1b, LPS
or by their downstream signaling molecules, and that its biolog-
ical function is conserved between humans and mice as well as
among multiple cell types.
NLRC5 Interacts with IKKa/IKKb in Unstimulated
and Stimulated Cells
Results presented in Figures 2B and 2D suggest that NLRC5
may directly interact with IKKa, IKKb or NEMO to inhibit NF-kB
activation. To test this prediction, we transfected 293T cells
with HA-tagged NLRC5 together with Flag-tagged IKKa, Flag-
tagged IKKb or Flag-tagged NEMO expression plasmids. Coim-
munoprecipitation and western blot analyses revealed that
NLRC5 interacted with IKKa and IKKb subunits, but not with
NEMO, although the corresponding proteins were readily
detected in whole-cell lysates (Figure 3A). Notably, NLRC5 did
not interact with either TAK1 or MEKK3 upstream of IKK
(Figure S3A). To further test whether NLRC5 can interact with
endogenous IKKa/b, we immunoprecipitated 293T cell lysates
with an isotype IgG or anti-NLRC5 antibody, followed by western
blot analysis with the anti-IKKa/b, anti-NEMO or anti-NLRC5
antibody. As shown in Figure 3B, the IKKa/b, but not NEMO,
could be detected in the anti-NLRC5 or anti-mNLRC5-immuno-
precipitants. Such an interaction between NLRC5 and IKKa/b
was also observed when anti-IKKa/b and anti-NEMO antibodies
were used for immunoprecipitation (Figure S3B). These results
suggest that NLRC5 can interact with IKKa/b, but not with
NEMO, under physiological conditions.
Since IKKa/b generally forms a complex with NEMO, a key
question is whether there are two distinct complexes in unstimu-
lated cells: IKKa/b/NEMO and IKKa/b/NLRC5. To address this
issue, we used different antibodies (anti-IKKa, anti-Flag and
anti-NEMO) to immunoprecipitate the IKK complexes containing
either NLRC5 or NEMO, and then determined the components of
their complexes. We found NEMO and NLRC5 in the anti-IKKa
immunoprecipitants, NLRC5 and IKKa/b (but not NEMO) in the
anti-Flag-NLRC5 immunoprecipitants, and IKKa/b and NEMO
(but not NLRC5) in the anti-NEMO immunoprecipitants (Fig-
ure S3C), suggesting that the IKKa/b/NEMO and IKKa/b/
NLRC5 complexes coexist in unstimulated cells. To definitively
demonstrate the presence of two distinct complexes, we frac-
tionated cell extracts of RAW264.7 on a size-exclusion column
(HiPrep 16/60 Sephacryl S-300 HR). Immunoblotting of fractions486 Cell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc.collected from chromatography showed that IKKa/b mainly coe-
luted with NEMO in fractions 22–31 (molecular mass about 700
kDa) (Figure 3C), consistent with a previous report (Rothwarf
et al., 1998). In contrast, NLRC5 mainly eluted in fractions 15-18
(molecular mass about 1100 kDa), which also contained IKKa/
b but no NEMO (Figure 3C), suggesting that NLRC5 forms
a larger complex with IKKa/b than previously reported for the
IKKa/b/NEMO complex, thus confirming the coexistence of
IKKa/b/NLRC5 and IKKa/b/NEMO complexes in unstimulated
cells.
To determine the dynamics of NLRC5 interaction with IKKa/
b after stimulation, we treated RAW264.7 cells with LPS, col-
lected them at different time points and performed immunopre-
cipitation and western blot analyses. The interaction between
NLRC5 and IKKa/b was reduced at 30 min, but was restored
at 60 min after LPS stimulation (Figure S4A). This oscillating
pattern of interaction correlated inversely with IKK phosphoryla-
tion (p-IKK) during the first 60 min posttreatment and then dimin-
ished or even disappeared after 2 hr of treatment (Figures S4A–
S4C), suggesting that the negative regulatory activity of NLRC5
is signal-dependent, but is not affected exclusively by protein
concentration.
NLRC5 Competes with NEMO for IKKa/IKKb and Inhibits
Their Phosphorylation and Kinase Activity
We next tested whether NLRC5 and NEMO compete each other
for binding to IKKa/b. 293T cells were transfected with a fixed
concentration of Flag-NLRC5 and HA-IKKb DNAs, together
with increasing concentrations of HA-NEMO DNA. Coimmuno-
precipitation and immunoblot revealed that the binding between
NLRC5 and IKKb was markedly decreased with increasing con-
centrations of NEMO (Figure 3D). Although the phosphoryla-
tion and kinase activity of IKKa/b could be detected in the
IKKa/b/NEMO complex after LPS stimulation, they decreased
with increasing amounts of transfected NLRC5. There were no
detectable phosphorylation and kinase activity of IKKa/b in
the IKKa/b/NLRC5 complex (Figure 3E). Importantly, increasing
amounts of NLRC5 had more pronouced effects on the phos-
phorylation and kinase activity of IKKa/b in the total and
NEMO-immunoprecipitated IKKa/b fraction than on its changes
at the protein level (Figure 3E). These results suggest that NLRC5
not only competes with NEMO for IKKa/b binding, but also
inhibits IKKa/b phosphorylation and its ability to phosphorylate
IkB or free IKKa/IKKb. To test this possibility, we performed
experiments with constitutively active IKKa (SS176/180/EE)
or IKKb (SS177/181/EE) mutants and found that NLRC5 inter-
acted with constitutively active IKKa (EE) and IKKb (EE) (Fig-
ure S4D). Kinase assays revealed that expression of NLRC5
inhibited the ability of IKKa (EE) and IKKb (EE) to phosphorylate
IkB (i.e., 32p-GST-IkBa), as well as their ability to autophosphor-
ylate IKK (i.e., 32p-IKK) (Figure S4E). These observations were
further supported by NF-kB-luc assays showing that NLRC5
can inhibit NF-kB activation by the constitutively active IKKa
(EE) and IKKb (EE) (Figure S4F). These results suggest that
NLRC5 can inhibit the ability of active IKKa/IKKb to phosphory-
late IkBa or free IKKa/IKKb.
To determine how NLRC5 inhibits the phosphorylation of
IKK, we sought to identify the domain of IKKb responsible
Figure 3. NLRC5 Interacts with IKKa and IKKb to Inhibit Their Phosphorylation
(A) 293T cells transfected with Flag-IKKa, Flag-IKKb, Flag-NEMO and HA-NLRC5. HA-tagged NLRC5 protein was immunoprecipitated with anti-HA beads, and
blotted with anti-Flag.
(B) 293T and RAW264.7 cell extracts were immunoprecipitated with IgG, anti-NLRC5 or anti-mNLRC5 antibody, respectively, and then analyzed together with
whole-cell extracts by western blot with an anti-IKKa/b, anti-NEMO, anti-NLRC5 or anti-mNLRC5 antibody.
(C) Cell extracts of RAW264.7 cells were fractionated on a size-exclusion column (HiPrep 16/60 Sephacryl S-300 HR). The collected factions with an equal volume
were used for western blot analysis with specific antibodies. The elution positions of calibration proteins with known molecular masses (kDa) were used to deter-
mine the size of complexes.
(D) 293T cells were transfected with the indicated doses of Flag-NLRC5, HA-IKKb and HA-NEMO. Whole-cell extracts were immunoprecipitated with anti-Flag
beads and blotted with anti-HA.
(E) 293T/TLR4 cells were transfected with empty vector or different doses of HA-NLRC5 (0, 50 or 200 ng) DNA and then treated with LPS. Cell extracts were
collected at 30 min poststimulation and prepared for immunoprecipitation with anti-HA and anti-NEMO, followed by immunoblot (IB) with indicated antibodies
or kinase assay (KA).
(F) The domain structure of IKKb. Numbers in parentheses indicate amino acid position in construct. LZ, leucine zipper; HLH, helix-loop-helix.
(G) 293T cells were transfected with HA-NLRC5 and Flag-IKKb or various Flag-IKKbmutants. Whole-cell extracts were immunoprecipitated with anti-Flag beads,
and blotted with anti-HA.
(H and I) 293T cells transfected with IKKa, IKKb, JNK1, JNK2, andp38with or withoutHA-NLRC5were used to analyze the phosphorylation of IKKa/b, JNK and p38.
(J) RAW264.7 cells were treated with LPS and collected at the indicated time points. Cell extracts were prepared for immunoprecipitation with anti-mNLRC5 or anti-
NEMO, followed by immunoblot (IB) to determine the IKK phosphorylation with anti-p-IKK or anti-IKKa/b antibody and kinase activity of IKK.
See also Figure S3 and Figure S4.
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Figure 4. Interaction and Functional Anal-
ysis of NLRC5 Deletions in the Inhibition of
NF-kB Activation
(A) Four NLRC5 deletion constructs were
generated.
(B and C) 293T cells were transfected with NLRC5
and its mutations constructs, IKKb or kinase
domain of IKKb and analyzed by coimmunopreci-
pitation and western blot.
(D) 293T cells were transfected with NF-kB-luc
reporter, together with an empty vector, or with
full-length NLRC5 and its deletion constructs,
and analyzed for luciferase activity (fold induction).
(E) 293T cells were transfected with various
expression plasmids and the phosphorylation of
IKKa or IKKb was determined.
See also Figure S4G.for interacting with NLRC5. Because NEMO is known to bind
to the C terminus of IKKb (May et al., 2000), we generated dele-
tion mutants encompassing the amino-terminal kinase domain
(KD), leucine zipper domain (LZ) and a C-terminal helix-loop-
helix (HLH) domain of IKKb, and tested them for their ability
to interact with NLRC5 in an immunoprecipitation assay (Fig-
ure 3F). Like the full-length IKKb, the IKKb-KD construct strongly
interacted with NLRC5, while neither the IKKb-LZ nor the
IKKb-HLH construct showed appreciable binding activity with
NLRC5 (Figure 3G), indicating that NLRC5 specifically binds to
the IKKb-KD domain. However, because of the large size of
the NLRC5 protein, we considered that its binding to IKKb
might physically block any binding of NEMO to IKK (Figures 3D
and 3E).
We next tested the specificity of NLRC5-mediated inhibition of
IKK phosphorylation. As shown in Figures 3H and 3I, NLRC5
markedly inhibited the IKKa/b phosphorylation, but not p38 or
JNK phosphorylation, consistent with the observation that
NLRC5 did not interact with TAK1 or MEKK3 (Figure S3A).
Finally, we further tested the status of the phosphorylation and
kinase activity of IKKa/b in IKKa/b /NLRC5 and IKKa/b /NEMO
complexes in RAW264.7 cells under physiological conditions.
IKKa/b in the IKKa/IKKb/NLRC5 (NLRC5-IP) complex was not
phosphorylated and showed no kinase activity during LPS
stimulation. By contrast, IKKa/b in the IKKa/b /NEMO (NEMO-IP)
complex was phosphorylated and exhibited a strong kinase
activity after LPS stimulation (Figure 3J), suggesting that NLRC5
inhibits its phosphorylation and kinase activity in the IKKa/
IKKb/NLRC5 complex under physiological conditions.488 Cell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc.LRR Region Is Responsible
for NLRC5-Mediated Inhibition
of IKK Phosphorylation
To identify the functional domains of
NLRC5, we generated four deletion con-
structs: NLRC5-D1, containing the CARD
and NOD domains (aa 1–517); NLRC5-D2,
containing the LRR-R1 (aa 651-898);
NLRC5-D3, containing the linker region
and LRR-R2 (aa 900–1329); and NLRC5-
D4, containing the CARD domain andLRR-R3 (aa 1–215 plus 1471–1866) (Figure 4A). While all four
NLRC5 deletion constructs could interact with the full-length
IKKb protein as well as IKKb-KD (Figures 4B and 4C), NLRC5-
D3, like the full-length NLRC5, strongly inhibited NF-kB-luc
activity (Figure 4D). Other NLRC5 deletions showed either partial
or no inhibitory effect on NF-kB-luc activity. These results sug-
gest that NLRC5-D3 is required for the observed inhibition of
NF-kB activity by NLRC5.
To further investigate the molecular mechanism by which
NLRC5-D3 inhibits NF-kB activity, we tested whether these
deletions can inhibit the phosphorylation of IKKa/b. We found
that NLRC5-D3 strongly inhibited IKKa and IKKb phosphoryla-
tion, while NLRC5-D1, -D2 and -D4 produced little or weak inhi-
bition (Figure 4E). Notably, the inhibitory activity of these NLRC5
deletion mutants on the phosphorylation of IKKa and IKKb corre-
lated with their ability to inhibit NF-kB activation (Figure 4D), sug-
gesting that NLRC5-D3 inhibits NF-kB activation by blocking the
phosphorylation of IKK complexes. Unlike the full-length NLRC5,
however, NLRC5-D3 failed to compete with NEMO for binding to
IKKa/IKKb (Figure S4G), suggesting that the size of full-length
NLRC5 is critical for its ability to physically block NEMO from
interacting with IKKa/b.
Knockdown of NLRC5 Enhances NF-kB Activation
as Well as the Inflammatory Response
Since NLRC5 specifically interacts with IKKa/b and inhibits
NF-kB activation, we reasoned that knockdown ofNLRC5would
release IKKa/b for increased NF-kB activation under physiolog-
ical conditions. To test this prediction, we first demonstrated the
Figure 5. Knockdown of NLRC5 Can Signif-
icantly Enhance NF-kB Activation and
Inflammatory Responses
(A) Specific knockdown of NLRC5 or mNLRC5
was evaluated in various types of cells transfected
with NLRC5/mNLRC5 siRNA or scrambled siRNA.
(B) RAW264.7 cells were transfected with
mNLRC5 siRNA or scrambled siRNA, and then
treated with LPS. The cell extracts were harvested
at different time points and used for western blot
of various kinases and signaling proteins.
(C) The cell extracts of mNLRC5 knockdown and
control RAW264.7 cells after LPS treatment were
used for immunoprecipitation to obtain NEMO-
associated IKK (IP-1) and NEMO-free IKK (free
IKK and mNLRC5 associated IKK (IP-2). The phos-
phorylation of IKKa/b, the total amount of IKKa/b
and NEMO proteins in different fractions were
determined by anti-p-IKK, anti-IKKa/b or anti-
NEMO antibody.
(D) NLRC5 or mNLRC5 was knocked down in
293T/TLR4 and RAW264.7 cells. NF-kB-luc activ-
ity was determined after LPS treatment.
(E) ThemNLRC5 knockdown and control AW264.7
cells were treated with LPS for 1 h; the nuclear
proteins were harvested for NF-kB binding activity
determined by EMSA. Oct-1 DNA-binding com-
plexes served as a control.
(F) Endogenous NLRC5 was knocked down in
THP-1 and RAW264.7 cells and TNF-a and IL-6
production was measured after LPS treatment.
Data in panels (D) and (F) are presented as
means ± SEM. Asterisks indicate significant
differences between groups (*p < 0.05, **p < 0.01,
***p < 0.001 as determined by Student’s t test
analysis).
See also Figure S5.knockdown efficiency and specificity of NLRC5 or mNLRC5 at
both the mRNA and protein levels in various cell types with at
least two corresponding siRNAs, but not scrambled siRNAs
(Figure 5A and Figures S5A–S5C). We next tested the effect of
mNLRC5 knockdown on the phosphorylation of IKK, IkB, and
other kinases, including JNK, ERK, and p38. As shown in Fig-
ure 5B and Figure S5D, the phosphorylation of IKK (p-IKK) and
IkB (p-IkB) in the mNLRC5 knockdown cells was at least 3-fold
higher than that in the scrambled siRNA-transfected (control)
cells at 30 min after LPS treatment, although the total amounts
of IKK and IkB proteins were comparable between mNLRC5
knockdown and control cells. More importantly, we did notCell 141, 483–4observe any appreciable differences in
p-JNK, p-ERK and p-p38 between
mNLRC5 knockdown and control cells,
clearly indicating the specific inhibitory
effect of mNLRC5 on the phosphorylation
of IKK, but not on JNK, ERK, and p38
phosphorylation. Similar results were
obtained with human THP-1 cells (Fig-
ure S5E). Collectively, these results sug-
gest that specific knockdown of NLRC5
or mNLRC5 strongly enhances the phos-phorylation of the IKK complexes, but does not affect the phos-
phorylation of JNK, ERK, and p38 after LPS stimulation.
To further determine the molecular mechanisms by which
NLRC5 knockdown affects NF-kB signaling, we performed
two-step immunoprecipitations to obtain NEMO-associated IKK
(IP-1) and NEMO-free IKK (i.e., free IKK and NLRC5-associated
IKK, IP-2) (Figure 5C) and then compared the amounts of IKKa/
IKKb in each complex and their phosphorylation (p-IKK) in
mNLRC5 knockdown versus control cells. We found that the
total IKKa/b proteins in the NEMO-free IKK fraction (i.e., IP-2)
of mNLRC5 knockdown cells was slightly lower than that of
control cells, while IKKa/b in the IKKa/b/NEMO fraction (i.e.,96, April 30, 2010 ª2010 Elsevier Inc. 489
IP-1) in mNLRC5 knockdown cells was slightly higher than that
in control cells, suggesting that the reduction of IKKa/b /NLRC5
complex in mNLRC5 knockdown cells decreases the IKKa/b
proteins in the NEMO-free IKK fraction, but increases the
IKKa/b proteins in the NEMO/IKK complex (Figure 5C). Con-
sistent with this observation, we found that the phosphorylation
of IKK (p-IKK) in the NEMO-containing IP fraction (IP-1) in the
mNLRC5 knockdown cells was higher than that in control cells.
Importantly, even though the total IKKa/b in the NEMO-free frac-
tion (IP-2) of mNLRC5 knockdown cells was less than that of
control cells, its phosphorylation (p-IKK) level inmNLRC5 knock-
down cells was higher than that in control cells (Figure 5C), sug-
gesting thatmNLRC5 knockdown reduces the inhibition of phos-
phorylation of free IKKa/b. This notion agrees with data, showing
that NLRC5 interacts with constitutively active IKKa (EE) and
IKKb (EE) and inhibits their phosphorylation and kinase activity
(Figures S4D and S4E).
We next sought to determine whether the enhanced IKK phos-
phorylation seen with NLRC5 knockdown promotes NF-kB acti-
vation and NF-kB-dependent gene expression. Using the NF-kB-
luc reporter assay, we found that NLRC5 knockdown markedly
increased NF-kB-luc activity in 293T/TLR4 and RAW264.7 cells
after LPS treatment (Figure 5D). To directly demonstrate that
mNLRC5 knockdown enhances endogenous NF-kB activity,
we examined the DNA-binding activity of endogenous NF-kB.
Results in Figure 5E show that endogenous NF-kB activity in
mNLRC5 knockdown cells was at least 2-fold higher than that in
control cells. Consistent with this observation, knockdown of
NLRC5 or mNLRC5 resulted in markedly increased secretions
of NF-kB-responsive cytokines, such as TNF-a and IL-6, in both
mNLRC5 knockdown THP-1 and RAW264.7 cells (Figure 5F).
Hence, knockdown of NLRC5 or mNLRC5 enhances the IKKa/b
phosphorylation and NF-kB activity, thus increasing NF-kB-
dependent cytokine responses under physiological conditions.
NLRC5 Negatively Regulates Type I Interferon Signaling
by Interacting with RIG-I and MDA5
Recent studies show that NLRX1 inhibits the RIG-I-mediated
signaling pathway by targeting MAVS (Moore et al., 2008). To
determine whether NLRC5 might also be involved in the regula-
tion of type I interferon signaling, we performed functional assays
in TLR3-deficient 293T cells and found that intracellular poly(I:C)
activated IFN-b signaling, although such activation was strongly
inhibited by NLRC5 (Figure 6A), suggesting that NLRC5 func-
tions as a negative regulator of this antiviral pathway.
To determine the molecular mechanisms by which NLRC5
could inhibit the IFN-b response, we performed similar experi-
ments with different signaling molecules and found that RIG-I-
and MDA5-induced IFN-b-luc activities could be markedly
inhibited by increasing concentrations of NLRC5. However,
NLRC5 weakly inhibited MAVS- and TBK1-induced IFN-b-luc
activity and did not inhibit IKKi-induced IFN-b luciferase activity
(Figure 6A and Figure S6A). Furthermore, NLRC5 markedly
inhibited NF-kB-luc activity induced by intracellular poly(I:C),
RIG-I, MDA5, MAVS or TBK1 (Figure 6B). To determine whether
the weak inhibition of MAVS- and TBK1-induced IFN-b-luc activ-
ity by NLRC5 might be due to the inhibitory effect of NLRC5 on
IKK complexes, but not due to any direct effect on MAVS or490 Cell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc.TBK1, we transfected 293T cells with ISRE-luc, together with
RIG-I, MDA5, MAVS, or TBK1 in the presence or absence of
NLRC5. Both RIG-I- and MDA5-induced ISRE-luc activities
were potently inhibited, while MAVS- and TBK1-induced ISRE-
luc activities were not (Figure 6C), suggesting that NLRC5 inhibits
IFN-b activation by directly interacting with RIG-I and MDA5, but
not with MAVS or TBK1. Indeed, we found that NLRC5 was
strongly associated with RIG-I and MDA5, but did not interact
with MAVS, IKKi, TBK1, TRIF, TRAF3, or IRF3 (Figures 6D and
6E and Figure S6B). Thus, NLRC5 specifically binds to the
RIG-I and MDA5 proteins to inhibit the IFN-b response.
To further define the interaction between RIG-I and mNLRC5
under physiological conditions, we infected RAW264.7 cells
with VSV-eGFP and performed immunoprecipitation with anti-
mNLRC5 at different time points after VSV-eGFP infection.
We detected only a weak RIG-I protein band in anti-mNLRC5 im-
munoprecipitants at 4 hr postinfection; however, it peaked at 6 hr
and then became weak at 8 and 10 hr postinfection (Figure 6F).
Notably, RIG-I protein expression was also increased at 6 hr
postinfection (Figure 6F), consistent with previous observations
(Honda and Taniguchi, 2006). Importantly, IRF3 phosporylation
was observed at 4 hr and further increased at 6 hr postinfection,
indicating that VSV-eGFP infection activated the IRF3-depen-
dent signaling pathway. However, IKK phosphorylation and IkB
degradation were weak after VSV-eGFP infection (Figure 6F).
These results suggest that interaction between NLRC5 and
RIG-I is inducible after VSV-eGFP infection.
Because both the RIG-I protein level and IRF3 phosphorylation
peaked at 6 hr postinfection, coincident with the peak interaction
between mNLRC5 and RIG-I in RAW264.7 cells, we considered
that this interaction might critically rely on activating signal.
To test this possibility, we generated RIG-I-CARD and RIG-I-heli-
case constructs and tested their ability to interact with NLRC5.
Interestingly, NLRC5 strongly bound to the CARD domain of
RIG-I, but not to the helicase domain, while binding of NLRC5
to the CARD domain of RIG-I markedly exceeded that to the
full-length RIG-I (Figure 6G), suggesting that the CARD domain
becomes accessible only when RIG-I is activated by virus-
derived ligands. Furthermore, competition experiments revealed
that NLRC5 strongly inhibited the ability of MAVS to bind to RIG-I
(Figure 6H). Thus, it appears that the accessibility of the CARD
domain of RIG-I is critical for a productive interaction between
NLRC5 and RIG-I, and that such interaction may also be influ-
enced by the relative concentrations of MAVS and NLRC5.
To confirm the inhibitory effect of NLRC5 on the IRF3 phos-
phorylation, we assessed the phosphorylation states of IRF3
by overexpressing NLRC5 in 293T cells and found that NLRC5
potently blocked the phosphorylation of endogenous IRF3
induced by RIG-I, but not by MAVS (Figure 6I). In contrast,
NLRC5 or mNLRC5 knockdown in THP-1 and RAW264.7 cells
markedly increased IRF3 phosphorylation (Figure 6J). Thus,
NLRC5 can inhibit IFN-b signaling by blocking the binding of
MAVS to RIG-I and the IRF3 phosphorylation.
Knockdown of NLRC5 Enhances Innate
and Antiviral Immunity
To further demonstrate the effects of NLRC5 knockdown on
the expression of IFN-responsive genes, we knocked down
Figure 6. NLRC5 Negatively Regulates IFN-b Activation by Inhibiting RIG-I and MDA5 Function
(A–C) 293T cells were transfected withNF-kB-luc, INF-b-luc or ISRE-luc,NLRC5 plus poly(I:C)/Lyovec,RIG-I,MDA5,MAVS, TBK1, or IKKi plasmids and analyzed
for INF-b or ISRE luciferase activity. Values are means ± SEM of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
(D) 293T cells were transfected with HA-NLRC5 plus RIG-I, MAVS or IKKi. After immunoprecipitation with anti-HA beads, specific proteins were analyzed by
western blot with anti-Flag.
(E) 293T cells were transfected withMDA5with or withoutHA-NLRC5. After immunoprecipitation with anti-HA beads, specific proteins were analyzed by western
blot with anti-MDA5.
(F) RAW264.7 cells were infected with VSV-eGFP, and cell extracts were harvested at different time points, immunoprecipitated with anti-mNLRC5 antibody and
analyzed by western blot with anti-RIG-I.
(G) NLRC5 binds to the CARD domain of RIG-I. 293T cells were transfected withHA-NLRC5 plus Flag-RIG-I, Flag-RIG-ICARD domain and Helicase domain (HD).
After immunoprecipitation with anti-Flag beads, specific proteins were analyzed by western blot with anti-HA.
(H) NLRC5 competitively binds to RIG-I with MAVS. HEK293T cells were transfected with Flag-MAVS-HA plus Flag-RIG-1, or Flag-NLRC5. After immunoprecip-
itation with anti-HA beads, specific proteins were analyzed by western blot with anti-Flag.
(I) 293T cells were transfected with Flag-RIG-I and Flag-MAVS, with or without HA-NLRC5, and used for western blot analysis with anti-phospho-IRF3 and IRF3
antibodies.
(J) RAW264.7 and THP-1 cells were transfected with NLRC5/mNLRC5-specific siRNA or scrambled siRNA, respectively, and then infected with VSV-eGFP.
The cell extracts were harvested for western blot with anti-phospho-IRF3 and IRF3 antibodies.
See also Figure S6.
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Figure 7. Knockdown of NLRC5 Enhances Cytokine Response and Antiviral Immunity
(A and B) RAW264.7 cells or THP-1 cells were transfected with mNLRC5/NLRC5-specific siRNA or scrambled siRNA, followed by poly(I:C)/Lyovec treatment.
ISG-54, ISG-56, IFN-b mRNA and IFN-b protein were determined by real-time RT-PCR or ELISA.
(C) NLRC5 or mNLRC5 knockdown and control cells were infected with VSV-eGFP. Cell supernatants were used to measure IFN-b protein secretion by ELISA.
(D) RAW264.7 cells were transfected with mNLRC5 siRNA or scrambled siRNA for 36 hr and then treated with LPS, poly (I:C)/LyoVec (1 mg/ml) or VSV-eGFP
infection. Total RNAs from the treated cells were harvested at different time points and used for real-time PCR analysis to determine the expression of
TNF-a, IL-6, IFN-a, and IFN-b. The data in (A–D) are reported as means + SEM of three independent experiments. Asterisks indicate significant differences
between groups (*p < 0.05, **p < 0.01, ***p < 0.001 determined by Student’s t test analysis).
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endogenous NLRC5 or mNLRC5 and then treated the cells with
poly(I:C)/Lyovec or infected them with VSV-eGFP. Real-time
PCR analysis revealed that poly(I:C)/Lyovec treatment or infec-
tion with VSV-eGFP strongly increased mRNA levels of IFN-b
and the interferon-stimulating genes ISG54 and ISG56 in cells
transfected withmNLRC5- orNLRC5-specific siRNAs (Figure 7A
and Figure S7A), consistent with a previous study showing the
upregulation of IFN-b mRNA in A549 cells with NLRC5 knock-
down (Opitz et al., 2006). Furthermore, we found that poly(I:C)/
Lyovec treatment or VSV-eGFP infection led to a large increase
in the production of IFN-b protein in THP-1, RAW264.7, primary
murine macrophages and primary human monocytes trans-
fected with mNLRC5 or NLRC5-specific siRNA (Figures 7B and
7C and Figure S7B). We next determined their expression
patterns over time after stimulation or VSV infection, and found
that the NF-kB-responsive genes TNF-a and IL-6 in mNLRC5-
knockdown cells were upregulated as early as 2–4 hr after LPS
treatment, and IL-6 continued in that state for another 10 hr
(Figure 7D). No difference was found between mNLRC5 knock-
down and control cells, with the exception of IFN-b expression
at 8 hr after LPS treatment (Figure 7D). Similar experiments
with intracellular poly(I:C) treatment or VSV infection showed
strong upregulation of IRF3-responsive IFN-a and IFN-b expres-
sion, but little or no effect on TNF-a and IL-6 expression
(Figure 7D). Consistent with these observations, we found that
LPS treatment resulted in more IL-6 and TNF-a than IFN-b
protein, while VSV-eGFP infection led to more IFN-b than TNF-a
and IL-6 proteins in mNLRC5 knockdown RAW264.7 cells
(Figure S7C). It appears that stimulation with LPS leads to
more pronounced effects on NF-kB-regulated genes than does
either poly(I:C) treatment or VSV-eGFP infection, while the
converse is seen for IRF-3- regulated genes.
To demonstrate a link between increased innate cytokine
responses and antiviral immunity in NLRC5-silenced cells, we
showed that knockdown of endogenous NLRC5 or mNLRC5
rendered cells remarkably resistant to viral infection and reduced
the levels of VSV-eGFP-positive cells among 293T, THP-1, and
RAW264.7 cells, as well as MEFs and human monocytes (Fig-
ure 7E and Figure S7D). To monitor VSV-eGFP propagation in
both mNLRC5 knockdown and control cells, we performed
time course experiments and showed that GFP expression
from VSV-eGFP could be observed at 8 hr postinfection with
rapid propagation at 10 hr in control cells. More than 90% of
the cells were GFP positive at 12 hr. By contrast, GFP expression
from VSV-eGFP viruses could rarely be observed at 10 hr,
became visible at 12–14 hr, and remained limited to a few cells
even at 18 hr in mNLRC5-silenced cells (Figure S7E). At 15 hr,
the morphology of the cells was markedly changed in control
cells, but not in mNLRC5 knockdown cells (Figure S7F). At 20 hr,
most of the cells in control group had died with a striking reduc-
tion in the GFP signal, while the cells treated with mNLRC5
siRNA remained alive and appeared normal (Figure S7G). We
conclude that NLRC5 knockdown can significantly increase(E) 293T cells, THP-1 cells and RAW264.7 cells were transfected with NLRC5-, m
Viral infections were analyzed by fluorescence microscopy (with phase contrast
(F) Proposed model illustrating how NLRC5 negatively regulates both NF-kB and
See also Figure S7.innate cytokine production and antiviral immunity against VSV-
eGFP infection and propagation.
DISCUSSION
Activation of innate immune receptors (TLRs, NLRs, and RLRs)
by their corresponding ligands initiates several key signaling
pathways, leading to the production of proinflammatory cyto-
kines, such as IL-6 and TNF-a, which in turn induce profound
positive feedback for adaptive immune responses (Akira et al.,
2006; Honda and Taniguchi, 2006). Increasing evidence indi-
cates that many inflammation-associated diseases may result
from dysregulated innate immunity (Inohara et al., 2005; Ting
et al., 2006). More recently, IL-1, IL-6, and TNF-a produced by
innate immune cells in chronic inflammation conditions have
been shown to promote cancer development and progression
(Karin et al., 2006). Thus, an understanding of the molecular
mechanisms by which innate immunity is held in check through
negative regulators appears critical for developing novel and
more effective treatments for inflammation-induced autoim-
mune diseases and cancer (Wang et al., 2008).
Both NF-kB and type I interferon signaling are controlled at
multiple levels by distinct mechanisms, whose regulatory pro-
teins may themselves be direct transcriptional targets of NF-kB
and type I interferon signaling, contributing to a negative regula-
tory feedback loop (Komuro et al., 2008). For example, expres-
sion of the A20, CYLD, and DUBA negative regulators is con-
trolled by NF-kB activity, while the RIG-I and MDA5 genes are
transcriptionally regulated by type I interferon signaling (Komuro
et al., 2008). We similarly observed the upregulation of NLRC5 or
mNLRC5 at both the mRNA and protein levels after 6 hr of treat-
ment with LPS. Such upregulation was abolished in MyD88-defi-
cient macrophages, suggesting that expression of NLRC5 itself
is under the control of MyD88-NF-kB pathways and forms
a negative regulatory feedback loop.
It has been demonstrated that the deubiquitinating enzymes
A20 and CYLD inhibit NF-kB signaling by targeting TRAF6
upstream of IKK (Kovalenko et al., 2003; Liew et al., 2005; Trom-
pouki et al., 2003; Wertz et al., 2004), while the deubiquitinating
protein DUBA inhibits type I interferon activity by targeting
TRAF3 (Kayagaki et al., 2007). Despite the importance of IKK
as a central transducer of signaling from cytokines, TLRs and
RLRs, leading to NF-kB activation, relatively little is known about
its negative regulation. Our findings show that NLRC5 blocks IKK
phosphorylation and thus NF-kB activation by interacting with
IKKa and IKKb, but not with the regulatory subunit NEMO.
To elucidate the mechanism(s) by which NLRC5 inhibits IKK
function, we provide evidence that NLRC5 forms a large com-
plex with IKKa/b, in addition to the previously described stable
IKKa/b/NEMO complex that seems to be dominant in unstimu-
lated cells (Rothwarf et al., 1998). The interaction between
NLRC5 and IKKa/b appears to be dynamic during the early
phase (1–2 hr) of LPS stimulation and correlates inversely withNLRC5-specific siRNA or scrambled siRNA, and then infected with VSV-eGFP.
as a control) as well as FACS analysis.
type I IFN signaling pathways. Auto-p, autophosphorylation.
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the phosphorylation of IKKa/b (p-IKK). This oscillation pattern
diminishes or even disappears with time after LPS stimulation,
suggesting the importance of this activating signal in the regu-
lation of the interaction between NLRC5 and IKKa/b. NLRC5
knockdown experiments showed increased cytokine responses
inNLRC5-silenced cells compared with control cells, suggesting
that the NLRC5 protein concentration is also an important fac-
tor in the regulation of the IKK activity. Overall, it appears that
both the LPS-induced activating signals and the relative protein
concentration of NLRC5 influence the interaction between
NLRC5 and IKKa/b, as well as the phosphorylation of IKK.
Although NLRC5 is ubiquitinated at about 30–40 min after LPS
stimulation (data not shown), further studies are needed to
determine whether the ubiquitination of NLRC5 plays a role in
the interaction between NLRC5 and IKKa/b.
A recent study shows that CUEDC2 interacts with IKKa/b, but
not NEMO, and recruits PP1c to deactivate the IKK complex
by dephosphorylating IKKa/b (Li et al., 2008). In resting cells,
CUEDC2 binds to IKKa/b (but not NEMO) and undergoes tran-
sient disassociation and reassociation steps after TNF-a treat-
ment (Li et al., 2008), similar to the interaction we described
between NLRC5 and IKKa/b after LPS stimulation. We also
show that IKKa/b in the IKKa/b /NLRC5 complex is not phosphor-
ylated and lacks kinase activity, in contrast to IKKa/b in the IKKa/
IKKb /NEMO complex (Figures 3E and 3J). These studies clearly
indicate that besides NEMO, other important regulatory proteins
such as NLRC5 can control the phosphorylation and kinase
activity of IKK complex through sequestering active IKKa/b.
Although the kinase domain of IKKb specifically recognized by
NLRC5 differs from the NEMO- binding site at the C terminus of
IKKb (May et al., 2000), we show that NLRC5 physically blocks
the binding of NEMO to IKKa/b due to its large size (Figure 3E
and Figure S4G). Our results also show that NLRC5 can interact
with constitutively active forms of IKKa (EE) and IKKb (EE) and
inhibit their ability to phosphorylate IkBa, as well as their ability
to autophosphorylate IKK (Figures S4D and S4E). Importantly,
experiments with two-step immunoprecipitation provide further
evidence that mNLRC5 knockdown has striking effects on IKK
and NF-kB signaling (Figure 5C), probably through a modulating
dynamic balance between /IKKa/b/NLRC5 and /IKKa/b/NEMO
complexes as well as sequestering the active IKKa/b to form an
inactive IKKa/b/NLRC5 complex. Furthermore, it has been sug-
gested that the phosphorylation of Ser740 in IKKb and Ser68 in
NEMO by active IKK may disrupt the interaction between IKK
and NEMO (Hayden and Ghosh, 2008), thus allowing other
proteins, including NLRC5 orphosphatases, to interact withactive
IKK and terminate NF-kB signaling. These studies suggest that
NLRC5 plays a critical role in inhibiting the phosphorylation and
kinase activity of IKKa/b in NF-kB activation after LPS stimulation.
RIG-I and MDA5 are key receptors for triggering type I inter-
feron signaling pathways, and are controlled by positive and
negative regulators, such as TRIM25 and RNF125, through ubiq-
uitination (Arimoto et al., 2007; Gack et al., 2007). To test the
hypothesis that other proteins are involved in the regulation of
RLRs, we present evidence showing that NLRC5 can bind to
both RIG-I and MDA5 but not to their downstream signaling
molecules such as MAVS, TBK1, IKKi, TRAF3, or IRF3. These
findings support a dual regulatory role for NLRC5 that encom-494 Cell 141, 483–496, April 30, 2010 ª2010 Elsevier Inc.passes both NF-kB and type I interferon signaling. Importantly,
our results show that NLRC5 binds more strongly to the CARD
domain of RIG-I than to the full-length RIG-I, suggesting that
NLRC5 specifically recognizes the CARD domain when it
becomes accessible after viral infection or stimulation by its
ligands. This interpretation agrees with the proposed model for
RIG-I action, in which the CARD domain of inactive RIG-I is
masked by its intramolecular binding with the repressor domain
in the C terminus (Cui et al., 2008; Yoneyama and Fujita, 2009).
Once RIG-I is activated, the CARD domain is exposed for
binding to MAVS or NLRC5.
Based on the experimental data discussed above, we propose
a model to illustrate how NLRC5 could negatively control both
NF-kB and type I interferon signaling (Figure 7F). First, the
expression of NLRC5 itself is controlled by NF-kB activation,
thus forming a negative regulatory feedback loop. Second, the
key to modulating the activation of NF-kB by NLRC5 in stimu-
lated cells lies in the dynamic balance between NLRC5/IKKa/
IKKb and NEMO/IKKa/IKKb complexes, which is controlled
by signaling stimulation and relative protein (NLRC5 versus
NEMO) concentrations, as well as the ability of NLRC5 to inhibit
IKK phosphorylation and kinase activity by sequestering active
IKKa/IKKb during signaling amplification after LPS stimulation.
Thus, the striking effects of NLRC5 on NF-kB signaling and its
downstream cytokine target genes cannot be explained by
only a small fraction of the NLRC5/IKKa/IKKb complex being
in an unstimulated state. Third, in contrast to its regulation of
NF-kB activation, NLRC5 competes with MAVS for binding to
the CARD domain of RIG-I or MDA5 only after it is exposed by
ligand stimulation of these receptors, leading to dampened
activation of IRF3. The interaction between NLRC5 and RIG-I
is inducible after poly (I:C) treatment or VSV viral infection.
Although TLR activation, cytokine stimulation and viral infection
can activate both NF-kB and type I signaling pathways, but they
tend to have a much more pronounced effect on either NF-kB-
regulated genes (e.g., LPS stimulation) or IRF3-regulated genes
(poly(I:C) or VSV infection). This selectivity appears to reflect the
different mechanisms by which NLRC5 regulates IKK activity or
RIG-I/MDA5 proteins. The ultimate outcome of NLRC5 inhibition
is determined by whether target gene promoters require NF-kB,
IRF3, or both transcription factors for gene expression.
Finally, we show that specific knockdown of NLRC5 not only
enhances NF-kB and type I interferon signaling and expression
of their target genes, but also increases antiviral immunity in
multiple cell lines and primary cells. Because of the conserved
biological function of NLRC5 in humans and mice, as well as in
various cell types, it appears to play a physiologically important
role in the maintenance of immune homeostasis, especially
with regard to regulation of the innate immune responses.
Hence, NLRC5 may provide a useful therapeutic target for
enhancing immunity against microbial infections and inflamma-
tion-associated diseases.EXPERIMENTAL PROCEDURES
Molecular Cloning of Full-Length Human and Mouse NLRC5
A full-length NLRC5 cDNA was obtained from human PBMC cDNA by two-
step PCR and was then cloned into pcDNA3.1Z with HA tag sequence.
A similar strategy was used to clone mouse NLRC5. Both pcDNA-HA-NLRC5
and pcDNA-HA-mNLRC5were sequenced to verify the correct DNA sequence
and their open reading frames.
Expression Profile and Antibody Production
The expression profile of NLRC5 and mNLRC5 in different tissues was evalu-
ated by reverse transcriptase (RT)-PCR analysis. NLRC5 and mNLRC5
peptides were used to generate polyclonal antibodies by standard methods.
Luciferase Assays, Immunoblot, Immunoprecipitation, and Kinase
Assay
HEK293 cells were transfected with IFN-b, NF-kB, or ISRE luciferase plasmids
and HA-NLRC5. TNF-a, IL-1b, LPS as well as exogenous MyD88, TRAF6,
IKKa, IKKb, NEMO, p65 (NF-kB), RIG-I, MDA5, MAVS, and IKKi plasmids
were used as stimulators. Dual-luciferase kits (Promega) were used for subse-
quent analysis. For kinase assay, a fusion of glutathione S-transferase and
amino acids of 1–54 of IkBa (GST-IkBa) was used as the substrate. To deter-
mine the kinase activity of immuoprecipitated IKKa (EE) and IKKb (EE) to
autophosphorylate IKK, we added 32p-ATP to immunoprecipitatants and
incubated the mixture at 30C for 30 min. 32p-GST-IkBa (*p-GST-IkBa) and
32p-IKK (*p-IKK) were detected by autoradiography.
Protein Fractionation by Size-Exclusion Column
Cell extracts prepared from RAW264.7 cell with lysis buffer were centrifuged at
20,000 rpm for 20 min at 4C. Fifteen mg of protein in a volume of 1.5 ml was
loaded onto a size-exclusion column (HiPrep 16/60 Sephacryl S-300 HR) with
the capacity to separate the large protein complexes. Samples were fraction-
ated with a flow rate of 0.5 ml per min, and collected as 0.5 ml fractions after
passage through the void volume. Protein fractions were separated by SDS-
PAGE and detected by western blotting with antibodies against mNLRC5,
IKKa/b, or NEMO.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assays were performed by using the LightShift
Chemiluminescent EMSA kit from Pierce Biotechnology according to the
manufacturer’s standard protocol.
Real-Time PCR Analysis
First-strand cDNA was generated from total RNA using oligo-dT primers and
reverse transcriptase (Invitrogen). Real-time PCR was conducted with the
QuantiTect SYBR Green PCR Master Mix (QIAGEN) and specific primers on
an ABI Prism 7000 analyzer (Applied Biosystems).
Knockdown of NLRC5 and mNLRC5 by RNA Interference
NLRC5-specific, mNLRC5-specific and control (2-scramble mix) siRNA oligo-
nucleotides were obtained from Invitrogen and Integrated DNA Technologies,
and transfected into 293T, THP-1, RAW264.7 and primary cells with use of
Lipofactamine 2000 (Invitrogen) and various Nucleofector kits (one for each
cell type) according to the manufacturer’s instruction.
Statistical Analysis
The results of all quantitative experiments are reported as mean ±SEM of three
independent experiments. Comparisons between groups for Statistical Signif-
icance were performed with a two-tailed paired Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
2010.03.040.
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